Unique ID issued by UMIN | UMIN000005734 |
---|---|
Receipt number | R000006742 |
Scientific Title | The effects of therapeutic agents against hypertension, dyslipidemia or diabetes on cholesterol efflux capacity by HDL cholesterol |
Date of disclosure of the study information | 2014/01/01 |
Last modified on | 2017/06/11 14:36:44 |
The effects of therapeutic agents against hypertension, dyslipidemia or diabetes on cholesterol efflux capacity by HDL cholesterol
The effects of therapeutic agents on cholesterol efflux capacity by HDL cholesterol
The effects of therapeutic agents against hypertension, dyslipidemia or diabetes on cholesterol efflux capacity by HDL cholesterol
The effects of therapeutic agents on cholesterol efflux capacity by HDL cholesterol
Japan |
Hypertension, Dyslipidemia, Diabetes
Cardiology |
Others
NO
We examine the effects of therapeutic agents against hypertension, dyslipidemia and diabetes on cholesterol efflux capacity by HDL cholesterol.
Efficacy
Cholesterol efflux capacity by HDL cholesterol
pre beta-1, ApoA-I, ApoA-II, oxidative stress marker(T-BARS) etc.
Interventional
Parallel
Non-randomized
Open -no one is blinded
No treatment
10
Treatment
Medicine |
Patients start to take Norvasc 5mg/day for hypertension.
Patients start to take Olmetec 20mg/day for hypertension.
Patients start to take Micardis 40mg/day
for hypertension.
Patients start to take Livaro 2mg/day
for dyslipidemia.
Patients start to take Lipitol 10mg/day
for dyslipidemia.
Patients start to take Crestol 5mg/day
for dyslipidemia.
Patients start to take Zetia 10mg/day
for dyslipidemia.
Patients start to take Bezatol SR 400mg/day for dyslipidemia.
Patients start to take Actos 30mg/day
for diabetes.
Patients start to take either Metfolmin 750mg/day or Voglibose 0.6mg/day for
diabetes.
20 | years-old | <= |
80 | years-old | > |
Male and Female
Patients who are diagnosed as hypertension, hypercholesteremia, hypertriglicemia, or type 2 diabetes according to their crieteria, take no medicine for each disease and consent to participate in this study
.Patients who have allergy for taking medicine
.Patients who have hepatic disorder(AST or ALT> 100IU/L),
biliary duct obstruction and
the following diseases with decreased hepatic function (acute hepatitis, acute exacerbation of chronic hepatitis, liver cirrhosis, liver cancer and jaundice)
.eGFR<60ml/min/1.73m2
.Diabetes patients treated with insulin.
.Female patients with the possibility of pregnancy
.Patients excluded by doctors
120
1st name | |
Middle name | |
Last name | Kimura Takeshi |
Graduate school of medicine, Kyoto University
Department of Cardiovascular medicine
54 Shogoin-kawahara-cho, Sakyo-ku, Kyoto
075-751-3190
kohono@kuhp.kyoto-u.ac.jp
1st name | |
Middle name | |
Last name | Koh Ono |
Graduate school of medicine, Kyoto University
Department of Cardiovascular medicine
54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto
075-751-3190
kohono@kuhp.kyoto-u.ac.jp
Dept. of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University
Ministry of education, culture, sports,
science and technology
Japanese Governmental office
NO
2014 | Year | 01 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2011 | Year | 06 | Month | 01 | Day |
2011 | Year | 08 | Month | 01 | Day |
2011 | Year | 06 | Month | 07 | Day |
2017 | Year | 06 | Month | 11 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006742
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |